Rodon Biologics

Rodon Biologics is an established, Lisbon-based biotech CRO/CDMO with a 20+ year track record in biologics development and manufacturing. The company offers a comprehensive suite of services including protein engineering, process development, stable cell line generation, microbial and mammalian production, downstream processing, and extensive analytical testing. Operating as a private, service-oriented business, Rodon supports biopharma clients in accelerating their therapeutic programs from early research to clinical supply, leveraging deep technical expertise across multiple expression platforms. Its model is built on collaborative partnerships to de-risk and streamline the biologics development pathway.

Integrated CRO/CDMO service platform encompassing microbial fermentation (E. coli, yeast), mammalian cell culture, cell line development, protein engineering, process development, analytical characterization, and GMP manufacturing for recombinant proteins and antibodies.

Rodon competes in the fragmented global biologics CRO/CDMO sector, which includes giants like Lonza, Catalent, and Samsung Biologics, as well as many specialized mid-sized and regional players. Its differentiation is likely based on its deep, 20-year expertise, integrated service offering, client-centric partnership model, and its position as a European provider. Competition is intense on capability, quality, speed, and cost.